Dysphagia and aspiration following chemo-irradiation of head and neck cancer: Major obstacles to intensification of therapy

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 363-364

  Eisbruch, Avraham ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; BARIUM; CISPLATIN; FLUOROURACIL; GEMCITABINE; RADIOSENSITIZING AGENT;

ASPIRATION PNEUMONIA; CANCER RADIOTHERAPY; CELL PROTECTION; COUGHING; DYSPHAGIA; EDITORIAL; FLUOROSCOPY; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDICAL ASSESSMENT; MUCOSA INFLAMMATION; PATIENT REFERRAL; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RELIABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPEECH THERAPY; SWALLOWING; TREATMENT OUTCOME; TUBE FEEDING; TUMOR CELL; VIDEORECORDING;

EID: 1842607620     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh117     Document Type: Editorial

References (23)

1. Fu KK, Pajak TF, Trotti A et al. A radiation oncology group phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2000; 48: 7-16.
2. Pignon JP, Bourhis J, Domenge C. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000; 355: 949-955.
3. Skladowski K, Maciejewski B, Golen M. Randomized clinical trial of 7-day continuous accelerated radiation (CAIR) of head and neck cancer: Report on 3-year tumor control and normal tissue toxicity. Radiother Oncol 2000; 55: 101-110.
4. Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: Results of a multicenter randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161-117.
5. Delaney GP, Fisher RJ, Smee RJ et al. Split-course accelerated therapy in head and neck cancer: An analysis of toxicity. Int J Radiat Oncol Biol Phys 1995; 32: 763-768.
6. Abitbol AA, Sridhar KS, Lewin AA. Hyperfractionated radiation therapy and 5-fluorouracyl, cisplatin and mitomycin C in the treatment of patients with locally advanced head and neck cancer. Cancer 1997; 80: 266-276.
7. Vokes EE, Stenson K, Rosen FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21: 320-326.
8. Kaanders JHM, van Daal WAJ, Hoogenraad WJ et al. Accelerated fractionation radiotherapy for laryngeal cancer, acute and law toxicity. Int J Radiat Oncol Biol Phys 1992; 24: 497-503.
9. Trotti A. Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys 2000; 47: 1-12.
10. Robbins KT. Barriers to winning the battle with head and neck cancer. Int J Radiat Oncol Biol Phys 2002; 53:4-5.
11. Nguyen NP, Moltz CC, Frank C et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 2004; 15: 383-388.
12. Logemann JA. Evaluation and treatment of swallowing disorders, second edition. Austin, TX: Proed 1998.
13. Eisbruch A, Lyden T, Bradford CR et al. Objective assessment of dysphagia and aspiration following chemo-irradiation for head and neck cancer. Int J Radiat Oncol Biol Phys 2002; 53: 23-28.
14. Brizel DM, Albers ME, Fisher RS et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-1804.
15. Peters L.J. Targeting hypoxia in head and neck cancer. Acta Oncol 2001; 40: 937-940.
16. Garden AS, Morrison WH, Wong S et al. Preliminary results of intensity modulated radiation therapy for small primary oropharyngeal carcinoma. Proceedings of the 45th Annual Meeting of ASTRO, 2003 (Abstr 2108).
17. Mittal BB, Kepka A, Mahadevan A et al. Use of IMRT to reduce toxicity from concurrent radiation and chemotherapy for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001; 51 (Suppl 1): 82 (Abstr 147).
18. Milano MT, Vokes EE, Witt ME et al. Retrospective comparison of IMRT and conventional three-dimensional RT in advanced head and neck patients treated with definitive chemoradiation. Proc Am Soc Clin Oncol 2003; 22: 499 (Abstr 2007).
19. Antonadou D, Throuvalas N, Petridis A et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2003; 57: 402-408.
20. Senzer N. A phase III randomized evaluation of amifostine in non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findings. Semin Oncol 2002; 29 (Suppl 6): 38-41.
21. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-3345.
22. Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Semin Oncol 2002; 29 (6 Suppl): 61-62.
23. Logemann JA, Radermaker AW, Pauloski BR et al. Effects of postural change on aspiration in head and neck patients. Otolaryngol Head Neck Surg 1994; 110: 222-227.